HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.

Abstract
A bispecific monoclonal antibody (bs-MAb) (OC/TR) was produced in large quantities for the intraperitoneal (i.p.) treatment of ovarian cancer. The bs-MAb recognizes the folate-binding protein on ovarian cancer cells on the one hand and the CD3 activation site on T lymphocytes on the other. T lymphocytes were expanded ex vivo, targeted with OC/TR in vitro and administered to the i.p. cavity in the presence of soluble OC/TR. All patients developed human anti-mouse-antibodies (HAMA). In the Dutch study, 2 complete remissions (CR) were seen, 2 partial regressions (PR), I stable disease (SD) and I progressive disease (PD). In the Italian study 3 CR, I PR, I SD and 2 PD were seen.
AuthorsR L Bolhuis, C H Lamers, S H Goey, A M Eggermont, J B Trimbos, G Stoter, A Lanzavecchia, E di Re, S Miotti, F Raspagliesi
JournalInternational journal of cancer. Supplement = Journal international du cancer. Supplement (Int J Cancer Suppl) Vol. 7 Pg. 78-81 ( 1992) ISSN: 0898-6924 [Print] United States
PMID1428412 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Antibodies, Monoclonal
  • Interleukin-2
Topics
  • Antibodies, Monoclonal (therapeutic use)
  • Antibody Formation
  • Cytotoxicity, Immunologic
  • Female
  • Humans
  • Immunotherapy, Adoptive
  • Interleukin-2 (therapeutic use)
  • Lymphocyte Activation
  • Ovarian Neoplasms (therapy)
  • T-Lymphocytes (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: